UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000028447
Receipt No. R000032563
Scientific Title Phase II Trial of Apixaban in Japanese Patients with Cancer-Associated Venous Thromboembolism
Date of disclosure of the study information 2017/08/01
Last modified on 2018/03/09

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Phase II Trial of Apixaban in Japanese Patients
with Cancer-Associated Venous Thromboembolism
Acronym J-CAV study
Scientific Title Phase II Trial of Apixaban in Japanese Patients
with Cancer-Associated Venous Thromboembolism
Scientific Title:Acronym J-CAV study
Region
Japan

Condition
Condition cancer-associated venous thromboemborism (CA-VTE)
Classification by specialty
Cardiology Hematology and clinical oncology
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To verify the reproductivity of the safety and efficacy of apixaban for Japanese CA-VTE
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2 Pragmatic
Developmental phase Phase II

Assessment
Primary outcomes incidence rate of the composite of major bleeding and clinically relevant non-major bleeding
Key secondary outcomes 1) incidence rate of the composite of recurrence of symptomatic VTE and VTE-related death
2) incidence rate of any bleeding
3) incidence rate of event-free survival (without VTE, major bleeding, and death)
4) duration of the hospitalizaion
5) colliration between Ottawa score and incidence rate of the composite of recurrence of symptomatic VTE and VTE-related death
6) colliration between Khorana score and incidence rate of the composite of recurrence of symptomatic VTE and VTE-related death

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Historical
Stratification NO
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Subjects will receive 10 mg b.i.d. apixaban for 7 days as an initial therapy, followed by 5 mg b.i.d. apixaban for 23 weeks as long-term therapy.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1) 20 years and older, both male and female
2) A diagnosis of cancer within six months before enrollment. Any treatment for cancer within the previous six months, or recurrent or metastatic cancer, or hematological malignancy without complete remission.
3) Objectively verified acute venous thrombosis
4) Informed consent
Key exclusion criteria 1) Hemodynamic instability
2) The patients will be treated with surgery or systemic thrombolysis for severe pulmonary embolism. Anticoagulant therapy prior to trial entry for > 7 days.
3) Subjects with an indication, other than VTE, intended for long-term anti-coagulant therapy, such as mechanical valve or arterial fibrillation
4) Use of a Factor Xa Inhibitor (e.g. apixaban, rivaroxaban, or edoxaban) =< 3 months prior to randomization
5) Thienopyridine therapy will be continued on study
6) Active bleeding or severe risk of bleeding
7) HIV protease inhibitor will be continued on study
8) Systemic use of Azole antifungals or Macrolide antibiotics at the time of registration
9) Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 3 or 4
10) Life expectancy < 6 months
11) Laboratory data
a) Platelet count < 50,000/mm^3
b) Calculated creatinine clearance < 30 ml/min using the Cockcroft-Gault formula
c) AST or ALT > 3 x UNL
d) PT-INR > 1.6
12) Clinically significant liver disease (e.g., acute hepatitis, chronic active hepatitis, or cirrhosis)
13) Severe hypersensitivity reaction to apixaban
14) Pregnant, breast-feeding, or unwilling to use adequate contraception
15) Other conditions inadequate for this research
Target sample size 62

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Hironobu Minami
Organization Kobe University Hospital
Division name Medical Oncology / Hematology
Zip code
Address 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Japan
TEL 078-382-5820
Email hminami@med.kobe-u.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Yoshinori Imamura
Organization Kobe University Hospital
Division name Medical Oncology / Hematology
Zip code
Address 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Japan
TEL 078-382-5820
Homepage URL
Email yimamura@med.kobe-u.ac.jp

Sponsor
Institute Kobe University Hospital, Medical Oncology / Hematology
Institute
Department

Funding Source
Organization Kobe University Hospital, Medical Oncology / Hematology
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 神戸大学医学部附属病院(兵庫県)、近畿大学医学部附属病院(大阪府)、大阪市立大学附属病院(大阪府)、神戸低侵襲がん医療センター(兵庫県)

Other administrative information
Date of disclosure of the study information
2017 Year 08 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2018 Year 01 Month 24 Day
Date of IRB
Anticipated trial start date
2018 Year 03 Month 01 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2017 Year 07 Month 31 Day
Last modified on
2018 Year 03 Month 09 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032563

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.